

29900061  
NSU  
USED BOOK  
\$24.25

# CARDIOPULMONARY PHARMACOLOGY

---

A HANDBOOK FOR CARDIOPULMONARY PRACTITIONERS  
AND OTHER ALLIED HEALTH PERSONNEL

SECOND EDITION

CYNTHIA L. HOWDER

# CARDIOPULMONARY PHARMACOLOGY

A Handbook for Cardiopulmonary Practitioners  
and Other Allied Health Personnel

---

CYNTHIA L. HOWDER, B.S.ED., R.R.T., C.P.F.T.

Respiratory Care Instructor  
Vincennes University  
Vincennes, Indiana



Y2002515



**Williams & Wilkins**

A WAVERLY COMPANY

BALTIMORE • PHILADELPHIA • LONDON • PARIS • BANGKOK  
BUENOS AIRES • HONG KONG • MUNICH • SYDNEY • TOKYO • WROCLAW

1996

Editor: Rhonda Kumm  
Manager Editor: Cathy Lee  
Production Coordinator: Barbara J. Felton  
Designer: Rita Baker-Schmidt  
Typesetter: Peirce Graphic Services  
Printer/Binder: Victor Graphics

Copyright © 1996 Williams & Wilkins

351 West Camden Street  
Baltimore, Maryland 21201-2436 USA

Rose Tree Corporate Center  
1400 North Providence Road  
Building 11, Suite 5025  
Media, Pennsylvania 19063-2043 USA



All rights reserved. This book is protected by copyright. No part of this book may be reproduced in any form or by any means, including photocopying, or utilized by any information storage and retrieval system without written permission from the copyright owner.

Accurate indications, adverse reactions and dosage schedules for drugs are provided in this book, but it is possible that they may change. The reader is urged to review the package information data of the manufacturers of the medications mentioned.

*Printed in the United States of America*

First Edition, 1992

### **Library of Congress Cataloging-in-Publication Data**

Howder, Cynthia L.

Cardiopulmonary pharmacology: a handbook for cardiopulmonary practitioners and other allied health personnel/Cynthia L. Howder. —2nd ed.

p. cm.

Includes bibliographical references and index.

ISBN 0-683-16313-2

1. Pulmonary pharmacology—Handbooks, manuals, etc.

2. Cardiopulmonary system—Effect of drugs on—Handbooks, manuals, etc. I. Title.

[DNLM: 1. Respiratory Tract Diseases—drug therapy. 2. Heart Diseases—drug therapy. 3. Allied Health Personnel. WF 145 H854c 1996]

RM388.H68 1996

616.1'2061—dc20

DNLM/DLC

for Library of Congress

96-686

CIP

*The publishers have made every effort to trace the copyright holders for borrowed material. If they have inadvertently overlooked any, they will be pleased to make the necessary arrangements at the first opportunity.*

To purchase additional copies of this book, call our customer service department at **(800) 638-0672** or fax orders to **(800) 447-8438**. For other book services, including chapter reprints and large quantity sales, ask for the Special Sales department.

Canadian customers should call **(800) 268-4178**, or fax **(905) 470-6780**. For all other calls originating outside of the United States, please call **(410) 528-4223** or fax us at **(410) 528-8550**.

**Visit Williams & Wilkins on the Internet:** <http://www.wwilkins.com> or contact our customer service department at [custserv@wwilkins.com](mailto:custserv@wwilkins.com). Williams & Wilkins customer service representatives are available from 8:30 am to 6:00 pm, EST, Monday through Friday, for telephone access.

96 97 98 98 00

1 2 3 4 5 6 7 8 9 10

This book is affectionately dedicated to all my students,  
past and present, who have taught me well.

## PREFACE

---

An extremely large number of drugs are used in the practice of cardiopulmonary medicine. They cannot be administered intelligently or safely without a sound knowledge base and understanding of their mechanisms of action, physiologic effects, side effects, toxicity, and kinetics. The primary purpose of ***Cardiopulmonary Pharmacology*** is to lay the foundation from which the student and practitioner can then build a safe and effective practice of administering drugs.

In Section I, the first seven chapters introduce the learner to drug therapy: principles and administration, phases of pharmacologic action and effect, drug interactions and modifications, evaluation, dosages and calculations, and drug preparation. Chapter 2, *Divisions of and Actions within the Autonomic Nervous System*, has been extensively revised with many new illustrations and tables. A new chapter has been added to this section: *Special Aspects of Neonatal, Pediatric, and Geriatric Drug Therapy*. These special population groups present a unique challenge to the practitioner because of their comparative physiologic variances to the normal adult population for which drugs are prescribed.

In Section II, the major portion of this handbook, Chapters 8 through 19 present the individual pharmacologic agents with criteria for use, administration, mechanisms of action and physiologic effects, contraindications, and adverse effects. A brief preparatory review of basic physiology and anatomy is included in many chapters to help the learner fully understand how a particular drug or drug class affects the body. Some chapters have been rearranged for clarity and consistency. For example, all of the bronchodilators have been placed in one chapter instead of three. A new topic has been added in Section II, *The Therapeutic Gases* (Chapter 8). This chapter details those gases that are uniquely administered through inhalation for their beneficial therapeutic properties.

To enhance the learner's awareness, each chapter has a list of learning outcomes, emphasizing the primary points and goals of the chapter.





# CONTENTS

---

<b>I</b>	<b>INTRODUCTION TO DRUG THERAPY</b>	<b>1</b>
<b>1</b>	<b>GENERAL PRINCIPLES OF PHARMACOLOGY</b>	<b>3</b>
	Learning outcomes	3
	Key terms	4
	Drug sources	4
	Drug nomenclature	5
	Drug standards	6
	Sources of drug information	6
	Drug legislation	8
	Legal factors	10
	Medication orders and prescription writing	10
	Research and clinical testing of drugs	12
	References/Recommended reading	16
<b>2</b>	<b>DIVISIONS OF AND ACTIONS WITHIN THE AUTONOMIC NERVOUS SYSTEM</b>	<b>17</b>
	Learning outcomes	17
	Key terms	18
	Review of neurons, synapses, and neurotransmitters	20
	Divisions of the nervous system	21
	The autonomic nervous system	23
	Local control substances	48
	Autonomic control by higher centers	54
	Pharmacologic modification of autonomic function	56
	References/Recommended reading	59

<b>3</b>	<b>PHASES OF DRUG EVENTS</b> .....	63
	Learning outcomes .....	63
	Key terms .....	65
	Part I: Pharmaceutical phase (drug administration) .....	66
	Part II: Pharmacokinetic phase (movement of drugs within the body) .....	80
	Part III: Pharmacodynamic phase (mechanism of action and effect of drugs) .....	87
	Physiologic nature of the lungs .....	88
	References/Recommended reading .....	90
<b>4</b>	<b>FACTORS THAT MODIFY DRUG EFFECTS</b> .....	91
	Learning outcomes .....	91
	Key terms .....	93
	Physiologic variables .....	93
	Pathologic factors .....	93
	Dose-effect relationship .....	95
	Compensatory reflex effects .....	98
	Biologic half-life .....	100
	Drug interactions .....	100
	Other factors that affect the therapeutic outcome of drugs .....	104
	References/Recommended reading .....	109
<b>5</b>	<b>THERAPEUTIC EVALUATION AND PREPARATION OF MEDICINES</b> .....	111
	Learning outcomes .....	111
	The four parts of therapeutic evaluation .....	112
	Rules for good charting .....	113
	What the law requires .....	115
	Identifying an adverse reaction .....	116
	Preparation of medicines .....	117
	References/Recommended reading .....	119
<b>6</b>	<b>MATHEMATICS OF DRUGS AND SOLUTIONS</b> .....	121
	Learning outcomes .....	121
	Methods of measurement .....	122
	Chemical solutions: definitions and terms .....	126
	Drug dosage calculations .....	127
	Dosage formulas for infants and children .....	141
	Intravenous calculations .....	141
	Summary .....	144
	References/Recommended reading .....	144



<b>7 SPECIAL ASPECTS OF NEONATAL, PEDIATRIC, AND GERIATRIC DRUG THERAPY</b>	147
Learning outcomes	147
Drug therapy in the neonatal and pediatric patient	147
Drug therapy in the geriatric patient	149
References/Recommended reading	151

## **II INDIVIDUAL PHARMACOLOGIC AGENTS** 153

<b>8 THE THERAPEUTIC GASES</b>	155
Learning outcomes	155
Oxygen	158
Carbon dioxide	170
Helium	173
Nitric oxide	175
References/Recommended reading	177

<b>9 COUGH AND COLD PREPARATIONS</b>	181
Nasal decongestants	182
Antihistamines	183
Antitussives	188
Expectorants	191
Cough and cold combinations	194
References/Recommended reading	195

<b>10 BRONCHODILATORS</b>	197
Sympathomimetic ( $\beta_2$ -adrenoceptor) bronchodilators	197
Anticholinergic (antimuscarinic) bronchodilators	216
Xanthine bronchodilators	228
References/Recommended reading	238

<b>11 PROPHYLACTIC ANTI-ASTHMATIC AGENTS</b>	243
Pathophysiology of asthma—an overview	243
Specific antiasthmatic agents	246
References/Recommended reading	250

<b>12 ANTI-INFLAMMATORY AGENTS</b>	251
The inflammatory response	251
Steroidal anti-inflammatory agents	253
Nonsteroidal anti-inflammatory drugs (NSAIDs)	266
References/Recommended reading	268

<b>13</b>	<b>MUCOKINETIC AGENTS AND SURFACE-ACTIVE AGENTS</b>	<b>269</b>
	Key terms	269
	Alveolar epithelium and the mucociliary system	270
	Properties of mucus	275
	Mucus production in disease states	277
	Methods of mucokinetics	278
	Specific therapeutic mucokinetic agents	279
	Surface-active agents	287
	Specific surface-active agents	288
	The gas exchange sites and pulmonary surfactant	289
	Pulmonary surfactant therapy	291
	New applications of pulmonary surfactant therapy	293
	Available surfactant preparations	293
	References/Recommended reading	298
<b>14</b>	<b>AGENTS THAT AFFECT SKELETAL MUSCLE CONTRACTION</b>	<b>301</b>
	Physiology of skeletal muscle contraction	301
	Cholinergic muscle stimulants	304
	Specific cholinergic muscle stimulants	307
	Neuromuscular blocking agents	310
	References/Recommended reading	319
<b>15</b>	<b>CENTRAL NERVOUS SYSTEM/VENTILATORY STIMULANTS AND DEPRESSANTS</b>	<b>321</b>
	The central nervous system—an overview	322
	CNS/Ventilatory stimulants	332
	Opioid agonists and antagonists	337
	Nonopioid analgesics	346
	Sedative-hypnotic agents	348
	Anesthetic agents	355
	Psychotherapeutic drugs	370
	Anticonvulsant agents	380
	References/Recommended reading	385
<b>16</b>	<b>ANTI-INFECTIVE AGENTS</b>	<b>387</b>
	Classification of anti-infective agents	387
	Staining techniques	390
	Specific antibacterial agents	391
	Miscellaneous antibacterial agents	408

Antituberculous drugs .....	414
Antifungal agents .....	417
Antiviral agents .....	424
Specific antiviral drugs .....	424
Agents used to treat <i>Pneumocystis carinii</i> pneumonia .....	428
References/Recommended reading .....	431
 <b>17 AGENTS AFFECTING RENAL FUNCTION AND ELECTROLYTE BALANCE</b> .....	<b>433</b>
Major body electrolytes .....	433
Renal physiology—an overview .....	441
Diuretic agents .....	445
Carbonic anhydrase inhibitors .....	445
Other carbonic anhydrase inhibitors .....	447
Thiazide diuretics .....	447
Loop diuretics .....	449
Osmotic diuretics .....	450
Potassium-sparing diuretics .....	452
References/Recommended reading .....	453
 <b>18 CARDIOVASCULAR AGENTS</b> .....	<b>455</b>
The cardiovascular system—an overview .....	455
Terminology associated with cardiovascular drugs .....	460
Normal hemodynamic parameters .....	462
Specific cardiovascular agents:	
Antianginal agents and vasodilators .....	468
Antiarrhythmic agents .....	475
Antihypertensive agents .....	495
Cardiotonic agents used in congestive heart failure .....	514
Vasopressors used in shock .....	518
Agents used in disorders of coagulation .....	530
References/Recommended reading .....	534
 <b>19 RESUSCITATION PHARMACOLOGY AND THE AMERICAN HEART ASSOCIATION'S ADVANCED CARDIAC LIFE SUPPORT GUIDELINES</b> .....	<b>537</b>
Primary resuscitation drugs .....	539
Oxygen .....	542
Epinephrine .....	544
Atropine .....	545
Lidocaine .....	546

Procainamide .....	546
Bretylium .....	547
Magnesium .....	548
Sodium bicarbonate .....	548
References/Recommended reading .....	549
<b>III APPENDICES .....</b>	<b>551</b>
<b>APPENDIX A: STANDARD MEDICAL AND         CARDIOPULMONARY ABBREVIATIONS         AND SYMBOLS .....</b>	<b>553</b>
<b>APPENDIX B: SELECTED BLOOD AND URINE STUDIES         FOR THE CARDIOPULMONARY PATIENT ...</b>	<b>581</b>
<b>APPENDIX C: APPROXIMATE DOSE EQUIVALENTS .....</b>	<b>607</b>
Index .....	609

# INTRODUCTION TO DRUG THERAPY

---

# I

Chapters 1 through 7 present the pharmacologic principles upon which the safe and effective administration of cardiopulmonary drugs is based. A thorough, solid understanding of these basic principles is necessary before preceding to Section II—The Individual Pharmacologic Agents.





# GENERAL PRINCIPLES OF PHARMACOLOGY

---

# 1

Comprehending drugs and their actions and effects is the basis of pharmacology. All drugs alter or enhance the body's own natural system through biochemical and physiological effects. The dose of a drug and the selectivity of a drug's effect are of special importance and are major considerations in therapeutics. Pharmacology is unique not only because it plays a significant part in medicine but also because it deals substantially with the mechanisms of action of biologically active substances.

The role of the practitioner in drug therapy mandates a sound foundation in pathophysiology and pharmacology. The practitioner must fully recognize the principles governing how drugs act upon the body and the various factors that alter a drug's action and effect and the consequences of any alteration. In addition, the practitioner should understand the legal and ethical issues that impact drug therapy.

## LEARNING OUTCOMES

*Upon completion of this chapter, the learner will be able to:*

1. Define the following terms: drug, pharmacology.
2. Specify the five types of drug sources and give an example of each.
3. List and define the various types of drug names.
4. Name the official publication for drug standards.
5. Identify the major sources of drug information.
6. Describe the various legislative acts that pertain to the sale and manufacture of drugs.
7. List and describe the four legal categories of drugs.
8. Identify the seven major components that should be included in a medication order.

## 4 INTRODUCTION TO DRUG THERAPY

9. Explain the major parts of the written prescription and define the following terms: superscription, inscription, subscription, and signature.
10. Associate a standard medical abbreviation used in drug orders with its meaning.
11. Discuss the process and procedures involved in the research and clinical testing of drugs.

### KEY TERMS

(The following key terms are highlighted in **bold** when they first occur in the text of this chapter.)

**Drug**—A chemical substance that exerts a biological effect. A drug may modify one or more of the body's functions and is used to diagnose, treat, or prevent a disease. The terms *medication* and *pharmacologic agent* are synonyms for the term *drug*.

**Pharmacology**—The study of drugs. Comprehensively, pharmacology is the study of drugs and their:

- origin
- chemical and physical properties
- sites of action within the body and physiologic effects
- influence within the body (mechanism of action)
- absorption, distribution, metabolism, and excretion from the body
- safe and effective dosage regimens and routes of administration
- adverse reactions and toxic effects

### DRUG SOURCES

Medicines have been known to man since the days of antiquity. Naturally derived sources of **drugs** used for medicinal purposes originated in the pre-Christian era, when remedies for common illnesses were treated with hot and cold applications, counterirritants, and medicinal herbs. The oldest known written record of drug mixtures dates from 2100 B.C. and is a legacy left by the ancient Sumerians. Significant discoveries were made by the ancient Egyptians, who used belladonna and narcotics such as mandrake and opium. Knowledge about these drugs was relatively limited and gained primarily from empirical observation. Over the centuries, the number of available drugs has increased tremendously and the knowledge of these drugs has become correspondingly more scientific. Currently, drugs originate from five major sources:

**Animal sources**—Examples include thyroxine (a purified compound obtained from the thyroid gland of an animal), used for the treatment of hypothyroidism, and insulin (an antidiabetic hormone), obtained from the pancreata of hogs, sheep, and cattle. Many vaccines also originate from animal sources.

**Vegetable or plant sources**—Examples include digitalis, which originates from the dried leaves of the purple foxglove plant, used in the treatment of congestive heart failure and cardiac arrhythmias. Another antiarrhythmic, quinidine sulfate, is the sulfate of an alkaloid obtained from cinchona bark. Atropine and scopolamine are obtained from the plant *Atropa belladonna*. Also, morphine sulfate, cocaine, nicotine, and caffeine all originate from parts of plants.

**Mineral sources**—These drugs are usually formed from acids, bases, and salts found in food. Calcium, potassium chloride, copper sulfate, and magnesium sulfate originate from mineral sources.

**Synthetic sources**—The most common sources of drugs today. This group is composed of compounds formed from the natural elements. Examples include meperidine (Demerol), an analgesic; diphenoxylate (Lomotil), an antidiarrheal medication; and the synthetic steroids and sulfonamides.

**Genetic engineering**—This relatively new and exciting source of drugs has opened a new concept to **pharmacology**. The most recent advances include the cloning and production of human insulin and tissue plasminogen activator (TPA). TPA is the newest thrombolytic agent used to treat myocardial infarction. Initially, TPA was isolated from blood and various tissues. However, the amounts that could be purified were not sufficient for any extensive use. TPA is now produced through genetically engineered cells in culture.

## DRUG NOMENCLATURE

Individual drugs may have many names. The formal name given to a drug is its *chemical* name, which consists of the drug's structural formula. A *code* name is given to a drug by a manufacturer while it is still in the development or research phase. If the drug appears therapeutically useful and the manufacturer wishes to market the drug, a *United States Adopted Name* (USAN) is selected by the USAN Council. The name assigned to the drug by the USAN Council is the drug's *nonproprietary* name, which is often referred to as the generic name. If the drug becomes fully approved for use and is admitted to *The United States Pharmacopeia* (see below), the USAN becomes the *official* name. Often, the nonproprietary and official names of a drug are the same; however, older drugs may differ in these names. The manufacturer, or legal owner, will also issue a *trade name*, or *proprietary* name, to the drug. A drug may be marketed by more than one manufacturer; therefore, one drug may have several proprietary names.

The nonproprietary, or generic, name of the drug should be referred to whenever possible because it leads to less confusion when a drug has several proprietary names. For purposes of identification, the generic name will be used throughout this text; if the proprietary name is mentioned, it will be in parentheses following the generic name.

Example: albuterol, salbutamol in Europe (Ventolin, Proventil, Respolin)